Barry Coller, MD
Barry Coller, MD
Vice President for Medical Affairs and Physician-in- Chief
David Rockefeller Professor
Allen and Frances Adler Laboratory of Blood and Vascular Biology
Dr. Barry Coller developed ReoPro® while studying platelet behavior at Stony Brook. During his research, he isolated an antibody that inhibited platelets from sticking together in arteries—a major cause of heart attacks. The antibody was found to be more effective than aspirin. Following FDA approval in 1994, ReoPro®, as the antibody was named, became the most commonly used treatment for angioplasty patients, making the procedure safer for use during heart attacks and as a preventative measure.
On September 1, 2001, Dr. Coller became the David Rockefeller Professor of Medicine; Head, Laboratory of Blood and Vascular Biology; Physician-in-Chief of The Rockefeller University Hospital; and Vice President for Medical Affairs at The Rockefeller University. He also serves as the founding Director of the Rockefeller University Center for Clinical and Translational Science and the Principal Investigator of the University’s Clinical and Translational Science Award (CTSA) from the National Center for Research Resources of the National Institutes of Health.
From 1993 to 2001, Dr. Coller was the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at Mount Sinai School of Medicine in New York City, as well as Chief of the Medical Service of the Mount Sinai Hospital, a component of The Mount Sinai-NYU Medical Center and Health System.
Dr. Coller received his B.A. degree, magna cum laude from Columbia College in 1966, and his M.D. from New York University School of Medicine in 1970. He completed his residency in internal medicine at Bellevue Hospital in New York City and advanced training in hematology and clinical pathology at the National Institutes of Health. He joined the faculty at Stony Brook in 1976 as an Assistant Professor of Medicine in the Division of Hematology. During his years at Stony Brook, he was the Clinical Director and Head of the Hematology Division, a consulting physician at the Northport VA Medical Center, Clinical Chief of the University Hospital Hematology Laboratory, a Director of the LI High Technology Incubator, a Director of the Stony Brook Foundation, and Associate Director for Biomedical Research of the Biotechnology Center for Advanced Technology. In 1982 Dr. Coller became Professor of Medicine and Pathology at Stony Brook. He was awarded the title of Distinguished Service Professor of Medicine and Pathology at Stony Brook in 1993.
Dr. Coller is a member of Phi Beta Kappa, Alpha Omega Alpha, the American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academies, and the National Academy of Sciences. He is a Fellow of the New York Academy of Medicine, the American Association for the Advancement of Science, and the American Academy of Arts & Sciences, and a Master of the American College of Physicians.
Dr. Coller served as President of the American Society of Hematology in 1997-1998, and currently serves as the founding President of the Society for Clinical and Translational Science, and as a member of the Advisory Council of the National Heart, Lung and Blood Institute and the national Principal Investigators’ CTSA Consortium Steering Committee.
Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoPro®; Centocor/Eli Lilly) was approved for human use by the FDA in 1994. It is now in clinical use throughout the United States, Europe, Scandinavia, Australia, and portions of Asia, to prevent ischemic complications of percutaneous coronary interventions such as angioplasty and stent insertion. More than 2.0 million patients have been treated with abciximab.
He also developed an assay to assess platelet function, and automated derivatives of that assay to monitor therapy with abciximab, aspirin, and clopidogrel (Plavix™) have been approved for human use by the FDA (VerifyNow; Accumetrics). Dr. Coller is the recipient or a co-recipient of thirteen U.S. patents.
Dr. Coller’s awards include:
- John Simon Guggenheim Memorial Foundation Fellow, 1982
- The International Investigator Recognition Award for Contributions to Hemostasis from the International Society on Thrombosis and Haemostasis, 1987
- National Heart Lung and Blood Institute MERIT Grant, 1989-1999
- c7E3 Fab (abciximab; ReoPro®) named 1995 Best New Therapeutic Product by the Biotechnology Industry Organization and Innovation of the Year by Pharmazeutische Zeitung
- 1997 Inventor of the Year, The New York Intellectual Property Law Association
- 1997 International Society on Thrombosis and Haemostasis Distinguished Career Award
- 1998 American Heart Association National Research Achievement Award (Co-recipient with Dr. Oliver Smithies)
- 1998 Jacobi Medallion, Mount Sinai Alumni Association
- 2001 Bugher Foundation Award for Achievement in Cardiovascular Science and Medicine, The New York Chapter of the American Heart Association
- 2001 Alexander Richman Award for Humanism in Medicine, Mount Sinai School of Medicine
- 2001 Warren Alpert Foundation Award (Co-recipient with Dr. Eugene Braunwald), Harvard Medical School
- 2002 Honorary Doctor of Science, Mount Sinai School of Medicine
- 2003 Honorary Doctor of Science, State University of New York at Stony Brook School of Medicine
- 2005 Robert J. and Claire Pasarow Foundation Award for Cardiovascular Research
- 2005 Henry M. Stratton Medal, American Society of Hematology
- 2007 Honorary Doctor of Science, North Shore-LIJ Graduate School of Molecular Medicine
Post-lecture webcast: www.medicinegr.org.
Access code: MEDICINE
This grand rounds is hosted by the Division of Hematology.